Hennion & Walsh Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $774K | Sell |
6,161
-146
| -2% | -$18.4K | 0.03% | 555 |
|
|
2025
Q1 | $698K | Buy |
6,307
+1,140
| +22% | +$126K | 0.03% | 559 |
|
|
2024
Q4 | $705K | Sell |
5,167
-4,413
| -46% | -$602K | 0.03% | 551 |
|
|
2024
Q3 | $1.1M | Buy |
9,580
+2,832
| +42% | +$326K | 0.05% | 429 |
|
|
2024
Q2 | $929K | Sell |
6,748
-57
| -0.8% | -$7.85K | 0.05% | 442 |
|
|
2024
Q1 | $939K | Buy |
6,805
+853
| +14% | +$118K | 0.05% | 435 |
|
|
2023
Q4 | $784K | Sell |
5,952
-83
| -1% | -$10.9K | 0.04% | 466 |
|
|
2023
Q3 | $679K | Buy |
6,035
+435
| +8% | +$48.9K | 0.04% | 445 |
|
|
2023
Q2 | $528K | Buy |
5,600
+113
| +2% | +$10.7K | 0.03% | 494 |
|
|
2023
Q1 | $555K | Buy |
5,487
+933
| +20% | +$94.4K | 0.03% | 488 |
|
|
2022
Q4 | $544K | Buy |
+4,554
| New | +$544K | 0.03% | 484 |
|
|
2021
Q2 | – | Sell |
-12,719
| Closed | -$1.24M | – | 741 |
|
|
2021
Q1 | $1.24M | Buy |
+12,719
| New | +$1.24M | 0.07% | 315 |
|